791111-79-0Relevant articles and documents
Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs
Diez-Torrubia, Alberto,García-Aparicio, Carlos,Cabrera, Silvia,De Meester, Ingrid,Balzarini, Jan,Camarasa, María-José,Velázquez, Sonsoles
supporting information; experimental part, p. 559 - 572 (2010/06/16)
Here we explore the applicability of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to a variety of amine-containing drugs. Efficient procedures have been developed for the synthesis of dipeptide and tetrapeptide amide prodrugs including
PRODRUGS CLEAVABLE BY CD26
-
Page/Page column 61, (2008/06/13)
The present invention provides a new prodrug technology and new prodrugs in order to increase the solubility, to modulate plasma protein binding or to enhance the biovailability of a drug. In the present invention the prodrugs are conjugates of a therapeutic compound and a peptide (eg tetrapeptide or hexapeptide) wherein the conjugate is cleavable by dipeptidyl-peptidases, more preferably by CD26, also known as DPPIV (dipeptidyl aminodipeptidase IV). The present invention furthermore provides a method of producing said prodrugs, to enhance brain and lymphatic delivery of drugs and/or to extend drug half-lives in plasma.